Clinical trials: Ulcerative Colitis in Remission
Colitis, Ulcerative
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
This Phase III, randomized, double-blind, parallel-grouped, placebo-controlled, multicenter study will investigate the efficacy and safety of etrolizumab in maintenance of remission in participants with moderately to severely…
- Trial name
- LAUREL (NCT02165215)
- Testing
- Etrolizumab
- Where
- 104 sites in United States, Brazil and 13 more
- Volunteers
- 359 people
- Sponsor
- Hoffmann-La Roche
Ulcerative Colitis
AppenDectomy Vs ANti TNF-a in Inducing Clinical and EnDoscopic Remission in Left-sided Ulcerative Colitis
Ulcerative Colitis (UC) is a chronic Inflammatory Bowel Disease (IBD) characterized by a multifactorial etiology, a variable involvement of large bowel, and a relapsing-remitting course.
- Trial name
- ADVANCED-UC (NCT05931458)
- Testing
- Appendectomy, Infliximab
- Volunteers
- 94 people
- Sponsor
- Federico II University
Colitis,Ulcerative
Anti-tumor Necrosis Factor in Patients With Ulcerative Colitis in Clinical Remission: to Continue or Not?
The primary objective is to assess if discontinuation of anti- tumor necrosis factor alpha (TNF) treatment in ulcerative colitis patients in sustained clinical remission, with the option to restart treatment in the case of…
- Trial name
- BIOSTOP (NCT03011268)
- Testing
- Discontinuation of anti-TNF treatment, Continuation of anti-TNF treatment
- Where
- 19 sites in Norway
- Volunteers
- 174 people
- Sponsor
- Helse Møre og Romsdal HF
Ulcerative Colitis
A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission
This study is a follow up study for subjects with Ulcerative Colitis (UC) in stable remission designed to evaluate flexible dosing of CP-690,550.
- Trial name
- NCT03281304
- Testing
- CP-690,500 5 mg, CP-690,550 10 mg
- Where
- 80 sites in United States, Belgium and 18 more
- Volunteers
- 140 people
- Sponsor
- Pfizer
Inflammatory Bowel Disease
Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab
Infliximab (IFX) is highly effective in inducing and maintaining remission in patients with inflammatory bowel disease (IBD). However, a large proportion of patients will eventually lose response to IFX.
- Trial name
- PRECISION (NCT02453776)
- Testing
- PRECISION dosing Infliximab
- Where
- Netherlands
- Volunteers
- 80 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Pediatric Crohn's Disease, Pediatric Ulcerative Colitis
Mission is Remission®: How Can a Disease Self-management Website Change Care?
Crohn's disease and ulcerative colitis, known together as inflammatory bowel disease (IBD), are chronic inflammatory conditions of the gastrointestinal tract.
- Trial name
- NCT02694042
- Testing
- Mission is Remission®
- Volunteers
- 39 people
- Sponsor
- IWK Health Centre
Ulcerative Colitis
Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission
This randomized, pilot phase I trial studies the side effects of berberine chloride in treating patients with ulcerative colitis and who are in remission (a decrease in or disappearance of signs and symptoms of cancer) to reduce…
- Trial name
- NCT02365480
- Testing
- Berberine Chloride, Laboratory Biomarker Analysis
- Where
- 2 sites in United States, China
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Inflammatory Bowel Disease (IBD), Crohn Disease (CD)
Assessment of Non-invasive Tools for Detecting Active Inflammatory Bowel Disease
Part of the success of the treatment of people living with inflammatory bowel diseases (IBD) depends on the information that the doctor can obtain from the different clinical tests.
- Conditions
- Inflammatory Bowel Disease (IBD), Crohn Disease (CD), Ulcerative Colitis (UC)
- Trial name
- NCT06722456
- Testing
- Analysis of protein signatures in stool samples
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Jean-François Beaulieu
Ulcerative Colitis
PRObiotic VSL#3® for Maintenance of Clinical and Endoscopic REMission in Ulcerative Colitis
Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by chronic inflammation limited to colonic mucosa. Its pathogenesis is not still clear, even if a multifactorial aetiology has been advocated.
- Trial name
- PROREM UC (NCT03415711)
- Testing
- VSL#3®, Mesalamine
- Where
- Italy
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- VSL Pharmaceuticals
Inflammatory Bowel Diseases (IBD), Remission of IBD
VIBRANT-IBD: Brain Effects of Non-Invasive Vagus Nerve Stimulation in IBD Remission
The VIBRANT-IBD study is a pilot, prospective, single-arm feasibility study investigating the effects of non-invasive vagus nerve stimulation (nVNS) in adults with inflammatory bowel disease (IBD) in clinical remission.
- Conditions
- Inflammatory Bowel Diseases (IBD), Remission of IBD, In Adults, Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis)
- Trial name
- VIBRANT-IBD (NCT07636304)
- Testing
- Non-invasive vagus nerve stimulation (nVNS)
- Where
- Poland
- Volunteers
- 15 people
- Sponsor
- University of Gdansk
Ulcerative Colitis
Combination of Diet and 5ASA ( 5-aminosalicylic Acid) for Ulcerative Colitis
Combination Therapy with Drug and Diet for Induction of Remission in Mild to Moderate Active Pediatric Ulcerative colitis: A Single Blinded, International Randomized Controlled Trial
- Trial name
- INDUCT (NCT03980405)
- Testing
- Group 1- Control Diet, Group 2- UCD Diet
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Prof. Arie Levine
Ulcerative Colitis
A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors
This Phase III, double-blind, placebo and active-comparator controlled, multicenter study will investigate the efficacy and safety of etrolizumab in induction of remission in participants with moderately to severely active…
- Trial name
- HIBISCUS I (NCT02163759)
- Testing
- Adalimumab, Etrolizumab
- Where
- 88 sites in United States, Argentina and 12 more
- Volunteers
- 358 people
- Sponsor
- Hoffmann-La Roche